The US Central Lab market revenue is projected to grow from $5,200 million in 2020 to $13,900 million by 2035. The surge is attributed to breakthroughs in laboratory automation, an expanding pipeline of clinical trials, and heightened demand for rapid and specialized testing. Year-over-year revenue growth underscores the impact of digital transformation, strategic partnerships, and regulatory support fostering innovation. Oncology and molecular diagnostics are expected to remain the leading segments, contributing substantially to overall market growth.
Read More - https://bussinessinsights.com/research-report/us-central-lab
Oncology dominates the US Central Lab market with a 38% share, driven by the rise in cancer incidences and the need for complex clinical trials. Cardiovascular applications account for 21%, reflecting higher demand for early disease detection. Infectious Diseases represent 15%, propelled by ongoing investments in pandemic preparedness. Endocrinology comes in at 11%, followed by Genetic Disorders at 9%, and Other applications at 6%. The focus on personalized medicine and increasing clinical research are catalysts for sustained growth across all segments.
Request Free Sample- https://bussinessinsights.com/request/telecommunication/us-central-lab
Who are the key players in US Central Lab industry?
Key players in the US Central Lab industry include LabCorp, Quest Diagnostics, ICON plc, Covance (LabCorp Drug Development), and Eurofins Scientific. These companies are recognized for their extensive service portfolios, advanced laboratory infrastructure, and partnerships with pharmaceutical clients for clinical trial management across the United States.
What is the US Central Lab growth?
The US Central Lab market has experienced strong recent growth, with companies like Quest Diagnostics reporting higher demand in 2023, driven by increased clinical trial activity and the growing need for specialized laboratory services, especially in support of oncology and genetic research.
Which segment accounted for the largest US Central Lab share?
The clinical trials segment accounted for the largest US Central Lab market share. Central labs supporting phase II and III clinical trials play an essential role in providing standardized testing, data management, and sample processing, with primary applications in oncology, infectious diseases, and chronic conditions.
Thanks & Regards,
Manisha C
sales [at] bussinessinsights.com